

## References

### I-9201

1. Onpattro prescribing information. Alnylam Pharmaceuticals, Inc. January 2023.
2. Tegsedi prescribing Information. Akcea Therapeutics, Inc. June 2022.
3. Cleveland Clinic. Amyloidosis: ATTR. <https://my.clevelandclinic.org/health/diseases/17855-amyloidosis-attr>
4. Kapoor M, Rossor AM, Laura M, et al. Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis. Journal of Neuromuscular Diseases. 6 (2019) 189-199. <https://content.iospress.com/download/journal-of-neuromuscular-diseases/jnd180371?id=journal-of-neuromuscular-diseases%2Fjnd180371>
5. Dyck PJ, Gonzalez-Duarte A, Obici L, et al. Development of Measures of Polyneuropathy Impairment in hATTR Amyloidosis: From NIS to mNIS+7. Journal of the Neurological Sciences. Volume 405, 15 October 2019. <https://www.sciencedirect.com/science/article/pii/S0022510X19303569>
6. Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care. Ther Clin Risk Manag. 2020;16:109-123. doi:10.2147/TCRM.S219979.
7. Amvuttra prescribing information. Alnylam Pharmaceuticals, Inc. February 2023.